Brief: Euronext: Quarterly Review Of CAC Family
Sept 11 (Reuters) - Pan-European stock exchange operator Euronext ENX.PA on Thursday announced its quarterly review of France's CAC family indices, effective from September 22. Here are the main changes: CAC 40 .FCHI
| Inclusion of | Exclusion of |
|---|---|
| Euronext | Teleperformance |
| Inclusion of | Exclusion of |
|---|---|
| Abivax | Esso |
| Exail Technologies | OVH |
| Inclusion of | Exclusion of |
|---|---|
| Technip Energies N.V. | Eurazeo SE |
| Teleperformance | Euronext |
| Inclusion of | Exclusion of |
|---|---|
| Technip Energies N.V. | Eurazeo SE |
| Inclusion of | Exclusion of |
|---|---|
| Abivax | Esso |
| Eurazeo | OVH |
| Exail Technologies | Technip Energies N.V. |
| Inclusion of | Exclusion of |
|---|---|
| Abeo | Abivax |
| Aelis Farma | Balyo |
| Antin Infrastructure Partners | Boiron |
| Ateme | Compagnie Chargeurs Invest |
| Esso | Dekuple |
| Explosifs Prod. Chi | Exail Technologies |
| Infotel | Haulotte Group |
| Linedata Services | |
| Maat Pharma | |
| OVH | |
| TFF Group | |
| TotalEnergies EP Gabon | |
| Transgene | |
| Vetoquinol | |
| Viel et Compagnie | |
| Vranken Pommery |
Recent news on Aelis Farma SA
See all newsBrief: Aelis Farma Availability Of 2025 Half-Year Financial Report
Brief: Euronext: Quarterly Review Of CAC Family
Brief: Aelis Farma Confirms Its 2025 Outlook
Brief: Aelis Farma Announces The Final Analysis Of Phase 2B Clinical Trial In Cannabis Use Disorder With AEF0117
Brief: Aelis Farma Says AEF0217 Well Tolerated With No Safety Concerns Identified